Webcast at 10:00 (CET), June 16 – top-line results HORIZON

Oncopeptides hosts a webcast on Tuesday, June 16 at 10.00 (CET) to provide comments on the full top-line results from the pivotal phase 2 HORIZON study. The webcast can be followed via the link: https://tv.streamfabriken.com/oncopeptides-2020-06-16. Shortly before the webcast, the presentation will be available below.

Dial-in numbers for Participants:
SE: +46 8 566 427 05
UK: +44 3333 009 262
US: +1 8332498406

Upcoming events

Silent Period

-

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

09:00 CET

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US. Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-